Tailoring therapy: balancing toxicity and chronic allograft dysfunction.
Halloran
P F
PF
Department of Medicine, Division of Nephrology & Immunology, University of Alberta, Edmonton, Alberta, Canada. phil.halloran@ualberta.ca
Melk
A
A
D000367:Age Factors; D065095:Calcineurin Inhibitors; D006084:Graft Rejection / Q000276:immunology / Q000503:physiopathology; D006085:Graft Survival; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000276:immunology / Q000503:physiopathology; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D016030:Kidney Transplantation; D019737:Transplants
D065095:Calcineurin Inhibitors; D006680:HLA Antigens; D007166:Immunosuppressive Agents